TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03107507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Given in a bolus dose first 50mg/kg as levetiracetam reaches a therapeutic serum level rapidly in 1.3 hours. Titration will not be attempted in our study to reach drug level rapidly and consequent rapid effective control of seizures. Maintenance dose is then given at a dose of 10 - 40mg/kg/day divided every 12 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital
Description: Phenobarbital is given intravenously in the form of a loading dose of 15mg/kg that can be repeated after a 20 minute interval not to exceed 30mg/kg then a maintenance dose 2-4 mg/kg/day divided every 12 hours.
Study: NCT01241006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 12mg PO single dose x 1 Placebo 1 capsule PO for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 60mg PO q day for 5 days
Study: NCT01828866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: EMDR is a protocolized, evidence-based treatment for PTSD. Here we use it to target addiction memory representations that elicit craving and may influence drinking behavior. The EMDR study protocol is based on the standard EMDR protocol and other EMDR approaches used in addiction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Reinforcement Approach
Description: CRA is based on behavioural therapy principles:~1. Functional analysis~2. Communication skills~3. Problem-solving skills~4. Sobriety sampling~5. Social networking~6. Refusal of substances~7. Reinforcing activities~8. Relapse management~9. Medication monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach
Description: CRA is based on behavioural therapy principles:~1. Functional analysis~2. Communication skills~3. Problem-solving skills~4. Sobriety sampling~5. Social networking~6. Refusal of substances~7. Reinforcing activities~8. Relapse management~9. Medication monitoring
Study: NCT03349411

Intervention type: DIAGNOSTIC_TEST
Intervention: Confusion Assessment Method
Description: This test is used for delirium assessment. The CAM consists of a series of questions, measuring attention (digits forward and backwards, days of the week and months of the year backwards), orientation (person, place, time), memory (immediate and delayed recall of 3 concrete nouns); and probing for any sleep, perceptual, or thinking disturbances. It was designed to incorporate DSM-III criteria for delirium.

Intervention type: DIAGNOSTIC_TEST
Intervention: Confusion Assessment Method
Description: This test is used for delirium assessment. The CAM consists of a series of questions, measuring attention (digits forward and backwards, days of the week and months of the year backwards), orientation (person, place, time), memory (immediate and delayed recall of 3 concrete nouns); and probing for any sleep, perceptual, or thinking disturbances. It was designed to incorporate DSM-III criteria for delirium.

Intervention type: DIAGNOSTIC_TEST
Intervention: Behavioral Inattention Test
Description: This test is used for neglect assessment. The BIT consists of 6 tasks: figure and shape copying; line, star, and letter cancellation, and representational drawing. Such tasks were shown to be appropriate in patients within 48 hours of stroke onset. Scoring of each test will include proportion of error responses on each test or deviation from midpoint on line bisection. Figure and shape copying and representational drawing will be scored based on each item completed.
Study: NCT03706469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 T2
Description: TAK-831 T2 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 T3
Description: TAK-831 T3 Tablets.
Study: NCT03349411

Intervention type: DIAGNOSTIC_TEST
Intervention: Behavioral Inattention Test
Description: This test is used for neglect assessment. The BIT consists of 6 tasks: figure and shape copying; line, star, and letter cancellation, and representational drawing. Such tasks were shown to be appropriate in patients within 48 hours of stroke onset. Scoring of each test will include proportion of error responses on each test or deviation from midpoint on line bisection. Figure and shape copying and representational drawing will be scored based on each item completed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Structural, functional and diffusion weighted scans will be obtained or acquired, depending on the cohort. Subacute sample participants will undergo a research MRI scan, whereas acute sample participants will allow the release of their clinical MRI scans.

Intervention type: DIAGNOSTIC_TEST
Intervention: Florida Mental Status Examination
Description: This test is used for mental status assessment, and it will be conducted in our subacute sample only. The FMSE tests memory, attention, language, visuospatial processing, and executive function. It will help to establish patients' mental status profile, including any deficits.

Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment
Description: MoCA is a brief cognitive screening tool for individuals with mild cognitive impairment and will be used in the acute sample.

Intervention type: DIAGNOSTIC_TEST
Intervention: Geriatric Depression Scale
Description: Because depression has been previously associated with delirium, patients will be evaluated for depression with the GDS. The GDS is a self-report measure consisting of 30 yes/no questions to measure depression in the elderly. It will be used as a covariate in data analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Geriatric Depression Scale
Description: Because depression has been previously associated with delirium, patients will be evaluated for depression with the GDS. The GDS is a self-report measure consisting of 30 yes/no questions to measure depression in the elderly. It will be used as a covariate in data analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Kessler Foundation Neglect Assessment Process
Description: This is a 10-category scale for spatial neglect based on observation of activities of daily living (e.g., eating, dressing, grooming, gaze orientation). Thee test is based on the Catherine Bergego Scale (CBS) and administered via the standardized KF-Neglect Assessment Process developed within our program.
Study: NCT04189055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 500mg/m² IV, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 500mg/m² IV, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180mg/m² IV, day 1
Study: NCT02719041

Intervention type: OTHER
Intervention: Immunohistochemistry staining method
Study: NCT03421405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroCatch Platform™
Description: NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
Study: NCT01211444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HGNS Treatment
Description: The Apnex Hypoglossal Nerve Stimulation System (HGNS) is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping and off when the patient is awake.
Study: NCT03292523

Intervention type: OTHER
Intervention: questionnaire
Description: Work Productivity and Activity Impairment (WPAI) Multidimensional Dyspnea Profile (MDP) Baseline Dyspnea Index (BDI), MOS-SF36, Hospital Anxiety Depression (HAD) Cognitive Failure Questionnaire (CFQ).
Study: NCT03666195

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Dioxide Nanoparticles
Description: incorporating titanium dioxide nanoparticles to PMMA, significantly decreases porosities in the denture resin, rendering titanium dioxide nanoparticles a suitable additive to denture base materials, as it also exhibits anti-microbial effects
Study: NCT01636622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.
Study: NCT03569215

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: All included patients will be exposed to questionnaires and psychiatric diagnostic tests

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: All included patients will be exposed to questionnaires and psychiatric diagnostic tests
Study: NCT02077725

Intervention type: OTHER
Intervention: interdisciplinary polypharmacy clinic visit
Study: NCT01672593

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy exploration and glue application
Description: A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device. Upon injection, two components, fibrinogen and thrombin, were mixed together in the mixing reservoir and yield a gelatin-like glue. This procedure was repeated in patients up to 3 times within 14-day FG treatment period.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy exploration and glue application
Description: A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device. Upon injection, two components, fibrinogen and thrombin, were mixed together in the mixing reservoir and yield a gelatin-like glue. This procedure was repeated in patients up to 3 times within 14-day FG treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Bacterial Agents
Description: Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Bacterial Agents
Description: Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition support
Description: Nutritional replacement and bowel rest via enteral or parenteral nutrition.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition support
Description: Nutritional replacement and bowel rest via enteral or parenteral nutrition.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRFG preparation
Description: As described in our previous work, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage.
Study: NCT01694888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lecture
Description: Teaching documentation skill using lecture method
Study: NCT00561899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP, amodiaquine, piperaquine, dihdroartemisinin
Description: once every month during september, October and November

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intermittent preventive treatment
Description: SP(500mg sulfadoxine/25mg pyrimethamine)1.25mg SP per kg stat Amodiaquine (200mg base) 25mg/kg over 3 days Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Du-Cotecxin
Description: Du-Cotecxin (40mg dihydroartemisinin (DHA/320mg Piperaquine (PQP) PQP/DHA 1.6/12.8mg/kg once daily for 3 days
Study: NCT04236232

Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid function
Description: Thyroid function,Lipid Profile, systolic Blood pressure ,diastolic blood pressure .Body Mass Index ,CRP,Echocardiography،ECG, Ultrasonography of Carotid artery

Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid function
Description: Thyroid function,Lipid Profile, systolic Blood pressure ,diastolic blood pressure .Body Mass Index ,CRP,Echocardiography،ECG, Ultrasonography of Carotid artery
Study: NCT02025855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04576845

Intervention type: OTHER
Intervention: Survey
Description: The children's eating behavior will be evaluated with Turkish validated Children's Eating Behavior Questionnaire - (CEBQ) by interviewing mothers face to face. The CEBQ is a Likert type, parent-report rating scale measuring the variation in eating behavior in children. The CEBQ consists of 35 items comprising eight subscales, each containing 3 to 6 items. Parents will be asked to rate their child's eating behavior on a five-point scale (never, rarely, sometimes, often, always; 1-5, respectively).
Study: NCT03451409

Intervention type: OTHER
Intervention: Tasked based functional MRI (fMRI)
Description: 2-3 brief computer tasks while brain activity is being measured. The tasks performed will involve making button press responses to letters, numbers or shapes on the computer screen.

Intervention type: OTHER
Intervention: Tasked based functional MRI (fMRI)
Description: 2-3 brief computer tasks while brain activity is being measured. The tasks performed will involve making button press responses to letters, numbers or shapes on the computer screen.

Intervention type: OTHER
Intervention: Tasked based functional MRI (fMRI)
Description: 2-3 brief computer tasks while brain activity is being measured. The tasks performed will involve making button press responses to letters, numbers or shapes on the computer screen.

Intervention type: OTHER
Intervention: Eye Tracking Device
Description: Camera aimed at eyes to record eye movements during tasks

Intervention type: OTHER
Intervention: Eye Tracking Device
Description: Camera aimed at eyes to record eye movements during tasks

Intervention type: OTHER
Intervention: Eye Tracking Device
Description: Camera aimed at eyes to record eye movements during tasks
Study: NCT03527498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baby treadmill
Description: The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation training
Description: Suitable for general physical rehabilitation training of all infants with cerebral palsy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical rehabilitation training
Description: Suitable for general physical rehabilitation training of all infants with cerebral palsy.
Study: NCT01423708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Administration of Everolimus within 24 hours from the time of randomization (7 days from the time of transplantation) in association with Tacrolimus and steroids. The first dose level of the trough will be performed at day 7 after initiation of therapy. After the reaching an Everolimus trough level of \>5ng/ml (final target 6-12 ng/ml), there will be a gradual weaning of tacrolimus (bringing Tacrolimus blood levels \<5 ng/ml) with discontinuation of Tacrolimus within 30 days after transplantation when possible.
Study: NCT00832000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexiletine
Description: 200 mg three times a day; in pill form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexiletine
Description: 200 mg three times a day; in pill form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo three times a day; in pill form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo three times a day; in pill form
Study: NCT03706469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 T3
Description: TAK-831 T3 Tablets.
Study: NCT02416245

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage powder fortified with micronutrients and Bacopa monnieri extract
Description: Test beverage powder is fortified with micronutrients and Bacopa monnieri extract. Each sachet contains 32g of treatmemt product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non fortified isocaloric control (without added micronutrients and Bacopa monnieri extract)
Description: Control beverage powder is the non-fortified isocaloric powder i.e. without micronutrients and Bacopa Monnieri extract. Each sachet contains 32g of placebo product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
Study: NCT03706469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 T3
Description: TAK-831 T3 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 T3
Description: TAK-831 T3 Tablets.
Study: NCT03562429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGF
Description: TGF is a powder formulation of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TGFP
Description: TGFP is 1/20 concentration of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
Study: NCT01651533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Practice Group
Description: Patients are administered rehabilitative therapy targeting their affected arms on 3 days/week during a ten week period. Directly after the therapy session, they participate in targeted mental practice session in which they cognitively rehearse the movement that they just physically practiced.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Group
Description: Individuals assigned to this group are administrated rehabilitative therapy targeting their affected arms in half four increments, occurring 3 days/week for 10 weeks. They also are administered an intervention in which they listen to a relaxation tape and/or tapes in which they receive instructions on exercises and information on stroke care.
Study: NCT02400814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 Monoclonal Antibody MPDL3280A
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 Monoclonal Antibody MPDL3280A
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 Monoclonal Antibody MPDL3280A
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SAR

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SAR

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SAR
Study: NCT02019641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET)
Description: walking on a treadmill at vigorous intensity for up to 45 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Weekly education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Weekly education
Study: NCT02734186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: Anthelminthic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: Anthelminthic
Study: NCT04016805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: * recombinant chimeric anti-CD20 monoclonal antibody~* administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: * recombinant chimeric anti-CD20 monoclonal antibody~* administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: * recombinant chimeric anti-CD20 monoclonal antibody~* administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: * Phosphoinositide-3-kinase (PI3K) delta inhibitor~* Tablet form, to taken orally on a daily basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: * Phosphoinositide-3-kinase (PI3K) delta inhibitor~* Tablet form, to taken orally on a daily basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: * Phosphoinositide-3-kinase (PI3K) delta inhibitor~* Tablet form, to taken orally on a daily basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: * Bruton Tyrosine Kinase (BTK) inhibitor~* Tablet form, to taken orally on a daily basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: * BCL-2 inhibitor~* Tablet form, to be taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Oral Capsule
Description: Kinase inhibitor, capsule form, to be taken orally